242 related articles for article (PubMed ID: 30926088)
1. The emerging role of measurable residual disease detection in AML in morphologic remission.
Buccisano F; Maurillo L; Schuurhuis GJ; Del Principe MI; Di Veroli A; Gurnari C; Venditti A
Semin Hematol; 2019 Apr; 56(2):125-130. PubMed ID: 30926088
[TBL] [Abstract][Full Text] [Related]
2. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
Fuda F; Chen W
Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
[TBL] [Abstract][Full Text] [Related]
3. Methods of Detection of Measurable Residual Disease in AML.
Zhou Y; Wood BL
Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
[TBL] [Abstract][Full Text] [Related]
4. Detection and management of acute myeloid leukemia measurable residual disease: is it standard of care?
Paterno G; Del Principe MI; Venditti A
Curr Opin Hematol; 2020 Mar; 27(2):81-87. PubMed ID: 31895104
[TBL] [Abstract][Full Text] [Related]
5. The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.
Buccisano F; Hourigan CS; Walter RB
Curr Hematol Malig Rep; 2017 Dec; 12(6):547-556. PubMed ID: 29027628
[TBL] [Abstract][Full Text] [Related]
6. Measurement of Residual Disease in Acute Myeloid Leukemia.
Vedula RS; Lindsley RC
Curr Hematol Malig Rep; 2017 Dec; 12(6):574-581. PubMed ID: 29064024
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
[TBL] [Abstract][Full Text] [Related]
8. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Xiao W; Petrova-Drus K; Roshal M
Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
[TBL] [Abstract][Full Text] [Related]
9. Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization.
Schuurhuis GJ; Ossenkoppele GJ; Kelder A; Cloos J
Expert Rev Hematol; 2018 Dec; 11(12):921-935. PubMed ID: 30466339
[No Abstract] [Full Text] [Related]
10. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia.
Buccisano F; Maurillo L; Del Principe MI; Di Veroli A; De Bellis E; Biagi A; Zizzari A; Rossi V; Rapisarda V; Amadori S; Voso MT; Lo-Coco F; Arcese W; Venditti A
Expert Rev Hematol; 2018 Apr; 11(4):307-313. PubMed ID: 29495904
[TBL] [Abstract][Full Text] [Related]
12. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
13. MRD in AML: does it already guide therapy decision-making?
Ossenkoppele G; Schuurhuis GJ
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):356-365. PubMed ID: 27913502
[TBL] [Abstract][Full Text] [Related]
14. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.
Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M
Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.
Buccisano F; Maurillo L; Del Principe MI; Del Poeta G; Sconocchia G; Lo-Coco F; Arcese W; Amadori S; Venditti A
Blood; 2012 Jan; 119(2):332-41. PubMed ID: 22039260
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia.
Canali A; Vergnolle I; Bertoli S; Largeaud L; Nicolau ML; Rieu JB; Tavitian S; Huguet F; Picard M; Bories P; Vial JP; Lechevalier N; Béné MC; Luquet I; Mansat-De Mas V; Delabesse E; Récher C; Vergez F
Clin Cancer Res; 2023 Jan; 29(1):134-142. PubMed ID: 36318706
[TBL] [Abstract][Full Text] [Related]
17. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
18. A mind map for managing minimal residual disease in acute myeloid leukemia.
Benton CB; Ravandi F
Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
[TBL] [Abstract][Full Text] [Related]
19. Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.
Tiong IS; Loo S
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902217
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease in acute myeloid leukemia: coming of age.
Paietta E
Hematology Am Soc Hematol Educ Program; 2012; 2012():35-42. PubMed ID: 23233558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
